RiboX’s Circular RNA CAR-T IND Clearance Forces the Industry to Rethink Everything It Knows About Cell Therapy Trial Design
FDA cleared RiboX's RXIM002 IND for the first circular RNA-based in vivo CAR-T therapy — here's what it means...
MicroRNA Therapeutics
CDR132L’s Phase 2 Miss: What a Well-Run Negative Trial Reveals About Heart Failure Drug Development
Cardior's CDR132L cleared safety hurdles in phase 2 but missed primary cardiac structure endpoints—a rigorous negative result that reshapes...